BCM
NVAX icon

BlueCrest Capital Management’s Novavax NVAX Stock Holding History

BlueCrest Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,015
Closed -$23K – 1018
2017
Q3 		$23K Buy
+1,015
New +$22.7K ﹤0.01% 826

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BlueCrest Capital Management's NVAX Position: Q4 2021 in Review

BlueCrest Capital Management sold out of Novavax (NVAX) in Q4 2021, closing a stake of 2,403 shares — an estimated $498K sold.

BlueCrest Capital Management first reported a position in NVAX in Q1 2016 and held it in 7 quarters. The position peaked at $498K in Q3 2021. 430 funds tracked by Wall St. Rank hold NVAX as of Q4 2021.

  • BlueCrest Capital Management reported no remaining Novavax position as of Q4 2021 after selling out during the quarter.
  • BlueCrest Capital Management sold 2,403 Novavax shares in Q4 2021, an estimated $498K.
  • BlueCrest Capital Management first reported a position in Novavax in Q1 2016 and held it in 7 quarters.
  • BlueCrest Capital Management's Novavax position peaked at $498K in Q3 2021.
  • 430 funds tracked by Wall St. Rank held Novavax as of Q4 2021.

Based on BlueCrest Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.